ATE205722T1 - Zusammenstellungen die insulin und den insulingleichen wachstumsfaktor-i (igf- i)enthalten - Google Patents

Zusammenstellungen die insulin und den insulingleichen wachstumsfaktor-i (igf- i)enthalten

Info

Publication number
ATE205722T1
ATE205722T1 AT97935259T AT97935259T ATE205722T1 AT E205722 T1 ATE205722 T1 AT E205722T1 AT 97935259 T AT97935259 T AT 97935259T AT 97935259 T AT97935259 T AT 97935259T AT E205722 T1 ATE205722 T1 AT E205722T1
Authority
AT
Austria
Prior art keywords
insulin
igf
growth factor
compositions containing
equal growth
Prior art date
Application number
AT97935259T
Other languages
English (en)
Inventor
Ross G Clark
James Q Oeswein
Douglas A Yeung
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE205722T1 publication Critical patent/ATE205722T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97935259T 1996-08-13 1997-07-31 Zusammenstellungen die insulin und den insulingleichen wachstumsfaktor-i (igf- i)enthalten ATE205722T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/696,314 US5783556A (en) 1996-08-13 1996-08-13 Formulated insulin-containing composition
PCT/US1997/013566 WO1998006423A1 (en) 1996-08-13 1997-07-31 Composition comprising insulin and insulin-like growth factor-i (igf-i)

Publications (1)

Publication Number Publication Date
ATE205722T1 true ATE205722T1 (de) 2001-10-15

Family

ID=24796556

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97935259T ATE205722T1 (de) 1996-08-13 1997-07-31 Zusammenstellungen die insulin und den insulingleichen wachstumsfaktor-i (igf- i)enthalten
AT01106315T ATE222120T1 (de) 1996-08-13 1997-07-31 Zusammensetzung die nph-insulin (neutral-protamin hagedorn insulin) enthält

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01106315T ATE222120T1 (de) 1996-08-13 1997-07-31 Zusammensetzung die nph-insulin (neutral-protamin hagedorn insulin) enthält

Country Status (16)

Country Link
US (1) US5783556A (de)
EP (2) EP0918536B1 (de)
JP (1) JP4187075B2 (de)
AR (1) AR009066A1 (de)
AT (2) ATE205722T1 (de)
AU (1) AU731745B2 (de)
CA (1) CA2261799C (de)
DE (2) DE69714796T2 (de)
DK (2) DK0918536T3 (de)
ES (2) ES2180523T3 (de)
HK (1) HK1042229B (de)
IL (1) IL128128A (de)
PT (2) PT918536E (de)
SI (1) SI1114644T1 (de)
WO (1) WO1998006423A1 (de)
ZA (1) ZA976598B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
AU718500B2 (en) * 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
EP1006794B1 (de) * 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
EP2583675A1 (de) * 1998-02-02 2013-04-24 Trustees Of Tufts College Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
AU763039B2 (en) * 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
DK1808438T3 (da) 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
FR2826278B1 (fr) * 2001-06-20 2005-03-25 Lipha Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
EP2316470A3 (de) 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetikuminhibitoren von post-Prolin-spaltenden Enzymen
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
RU2357750C2 (ru) 2002-12-31 2009-06-10 Элтус Фармасьютикалз Инк. Кристаллы человеческого гормона роста и способы их получения
BRPI0408105A (pt) * 2003-03-04 2006-03-01 Thetechnology Dev Company Ltd sistema de distribuição para droga e terapia celular
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor
US8989833B2 (en) 2004-07-13 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
WO2006125762A1 (en) * 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
US8097584B2 (en) * 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
IN2015DN00888A (de) 2006-02-22 2015-07-10 Mannkind Corp
EP2012817A2 (de) 2006-04-12 2009-01-14 Biodel, Inc. Insulinkombinationsformulierungen mit schneller wirkung und langzeitwirkung
US20090147006A1 (en) * 2007-12-07 2009-06-11 Roche Diagnostics Operations, Inc. Method and system for event based data comparison
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
EP2234644B1 (de) * 2008-01-04 2013-07-31 Biodel, Inc. Insulinformulierungen zur insulinfreisetzung als funktion des gewebeglukosespiegels
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010089706A1 (en) 2009-02-04 2010-08-12 Ecole Polytechnique Federale De Lausanne (Epfl) Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
EP2482724A2 (de) 2009-09-30 2012-08-08 Dexcom, Inc. Transkutaner analytsensor
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
MX2015006997A (es) * 2012-12-26 2015-09-23 Wockhardt Ltd Composicion farmaceutica.
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
MX2016008978A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3229828B1 (de) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MX2023004426A (es) * 2020-10-19 2023-08-04 Oak Hill Bio Ltd Composiciones adecuadas para su uso en neonatos.
DE102021122096A1 (de) * 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) * 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5091173A (en) * 1989-06-29 1992-02-25 The University Of Dundee Hair growth composition
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
JPH0818999B2 (ja) * 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
SG49239A1 (en) * 1991-05-24 1998-05-18 Amylin Pharmaceuticals Inc Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
JPH0543453A (ja) * 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd 創傷治癒促進用局所用徐放性製剤
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
EP0615452A4 (de) * 1991-11-25 1995-07-12 Inst Molecular Biology Inc Medikament zur unterstützung des wachstums von nerven in säugetieren.
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
WO1994000010A1 (en) * 1992-06-24 1994-01-06 Wilson Walter Rd Organic pesticide
DK0661990T3 (da) * 1992-08-26 2002-06-17 Celtrix Pharma Fremgangsmåde til systemisk behandling af kataboliske tilstande og systemisk vævsbeskadigelse
CA2132871A1 (en) * 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
WO1994016723A2 (en) * 1993-01-29 1994-08-04 Synergen, Inc. Wound healing composition
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
EP1044015B1 (de) * 1998-01-09 2008-10-08 Amylin Pharmaceuticals, Inc. Formulierungen für amylin peptidagonisten mit insulin
UA65636C2 (uk) * 1998-10-16 2004-04-15 Ново Нордіск А/С Стабільні концентровані препарати інсуліну для доставки через легені
AU763039B2 (en) * 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy

Also Published As

Publication number Publication date
JP2000516229A (ja) 2000-12-05
PT1114644E (pt) 2002-12-31
WO1998006423A1 (en) 1998-02-19
HK1042229B (en) 2003-08-15
EP0918536A1 (de) 1999-06-02
SI1114644T1 (en) 2002-12-31
PT918536E (pt) 2002-03-28
EP0918536B1 (de) 2001-09-19
AU3824397A (en) 1998-03-06
CA2261799A1 (en) 1998-02-19
DE69714796T2 (de) 2003-04-03
ES2162321T3 (es) 2001-12-16
CA2261799C (en) 2009-09-08
ES2180523T3 (es) 2003-02-16
ATE222120T1 (de) 2002-08-15
DK0918536T3 (da) 2001-12-03
AU731745B2 (en) 2001-04-05
IL128128A0 (en) 1999-11-30
AR009066A1 (es) 2000-03-08
DE69714796D1 (de) 2002-09-19
EP1114644B1 (de) 2002-08-14
EP1114644A1 (de) 2001-07-11
DE69706872D1 (de) 2001-10-25
IL128128A (en) 2007-06-17
US5783556A (en) 1998-07-21
JP4187075B2 (ja) 2008-11-26
DE69706872T2 (de) 2002-04-25
ZA976598B (en) 1999-02-17
DK1114644T3 (da) 2002-11-04
HK1042229A1 (en) 2002-08-09

Similar Documents

Publication Publication Date Title
ATE205722T1 (de) Zusammenstellungen die insulin und den insulingleichen wachstumsfaktor-i (igf- i)enthalten
ZA986823B (en) Cosmetic composition containing siloxane-based polyamides as thickening agents.
AP9801223A0 (en) Novel stable liquid paracetamol compositions and method for preparing same
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
DE69002795D1 (de) Stabilisierte, den epidermalen wachstumsfaktor enthaltende mittel.
FI964411A7 (fi) Tekstiilien puhdistuskoostumuksia, jotka sisältävät subtilisiini-BPN'- variantteja
EP0628603A3 (de) Feuchthärtende, aminoalkoxy-funktionelle Silicone enthaltende Zusammensetzungen.
OA09912A (en) Fungicides.
FI972309A7 (fi) 2-heterosyklyylioksi- ja tiometyyli-1,2,5-tiaditsolidin-3-oni-1,1-diok sideja, niitä sisältäviä koostumuksia ja menetelmä niiden valmistamise ksi
HUP9904242A3 (en) Microemulsion all purpose liquid disinfecting and cleaning compositions
ZA917486B (en) Polymeric endoscopic ligature.
IL112626A0 (en) Piperazines, their preparation and pharmaceutical or veterinary compositions containing them
OA09194A (en) "Insecticidal treatment and compositions therefor".
EP0670117A3 (de) Nahrungszusammensetzung mit niedriger Pufferungskapazität.
HUP9801051A3 (en) Arthropodicidal sulfur compounds, composition containing thereof and its use
IL114955A0 (en) N-substituted naphthofused lactams, pharmaceutical compositions containing them and their use
IL114541A0 (en) N-substituted or N,N'-disubstituted-N,N' diacylhydrazines and their use as insecticides
EP0612840A3 (de) Cyclische Verbindungen und ihre Anwendung als Riechstoffe.
IL91851A0 (en) Antimicrobial compositions containing 2,2-dibromo-2-nitroethanol and methods for killing microorganisms utilizing the same
ZA997511B (en) Novel heteroethynlene compounds and pharmaceutical and cosmetic compositions containing same.
IL118780A0 (en) Agricultural compositions containing glycolic acid
GB9420616D0 (en) Method, compositions and use
HUT77557A (hu) Fehérítő hatású szemcsés anyagok, alkalmazásuk és ezeket tartalmazó készítmények
EP0444605A3 (en) Angiotensin converting enzyme inhibitor, method for preparing it, composition containing the same and use thereof
IL114063A0 (en) Solution comprising IGF-I or any functional analogue thereof and method for its preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification